Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment candidate for newly diagnosed, relapsed or refractory multiple myeloma. Through this partnership, researchers will test clonoSEQ’s ability to both measure minimal residual disease (MRD) and determine the clinical value of monitoring MRD in isatuximab-treated patients. “MRD status is being...Continue Reading